



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

بسم الله الرحمن الرحيم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



MONA MAGHRABY

“Role of E-cadherin, DNA Zinc Finger Protein and Sex Determining Region Y-Box in Diagnosis of Breast Cancer”

**For The Partial Fulfillment of Master Degree
In Pharmacy (Biochemistry)**

Thesis submitted by

Salma Ahmed Mohamed Saad El-Din Salama
Bachelor Degree in Pharmaceutical Sciences from
Faculty of Pharmacy, Ain Shams University, 2010

Supervision Committee

Professor Dr.Hala Osman EL-Mesallamy

Professor of Biochemistry, Faculty of Pharmacy
Ain Shams University.

Dean of Faculty of Pharmacy - Sinai University

Professor Dr.Nadia Hamdy El Hefny

Professor of Biochemistry and Head of Biochemistry Department,
Faculty of Pharmacy
Ain Shams University.

Assistant Professor Dr.Reham Ali El-Shimy

Assistant professor of Clinical and Chemical Pathology
Department

National Cancer Institute, Cairo University.

Biochemistry Department

Faculty of Pharmacy

Ain Shams University

2021

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

"قُلْ سِيرُوا فِي الْأَرْضِ فَانظُرُوا كَيْفَ بَدَأَ
الْخَلْقَ ثُمَّ اللَّهُ يُنْشِئُ النَّشْأَةَ الْآخِرَةَ إِنَّ اللَّهَ عَلَى
كُلِّ شَيْءٍ قَدِيرٌ"

صدق الله العظيم

سورة العنكبوت (آية ٢٠)



Acknowledgements

Almighty Allah thank you for guidance, generosity, patience and blessings you give me in every single aspect in my life how forgivable and givable you are and how forgettable I am.

*I would like to express my deep appreciation to **Professor Dr. Hala Osman EL-Mesallamy**, Professor of Biochemistry, Faculty of pharmacy, Ain-shams University and Dean of Faculty of Pharmacy, Sinai University, for her keen supervision and guidance advice throughout the research program, which was fundamental in achieving the completion of this study.*

*I would like to express my heartfelt thanks and deep gratitude to **Professor Dr. Nadia Hamdy El Hefny**, Professor and Head of Department of Biochemistry, Faculty of Pharmacy, Ain Shams University, for being there all times, her valuable great efforts and help to get this study into light, continuous encouragement and advice during all stages of this work and above all the extreme support she gives me in everything in my life.*

*My sincere thanks and most appreciation to **Assistant Professor Dr. Reham Ali El Shimy**, Clinical and Chemical Pathology Department, National Cancer Institute, Cairo University, for her support, stimulating work, and fruitful assistance during the clinical course of this research.*

I would like to thank all our study volunteers, physicians whom participated, the nursing staff, and laboratory technicians for their assistance in performing the mentioned study.

*Last but not least, I would like to thank **my father professor Ahmed Saad El Din** and **my mother Hoda Bader** no words would express my gratitude and love for them they are simply life to me, my beloved husband **Mohamed Sabry** without his support after Allah I wouldn't have the energy to continue through all the phases of this degree, my siblings the backbone and all my family members and friends for their valuable support and help throughout all the phases of this study.*

Contents

List of abbreviations	I
List of figures.....	III
List of tables	V
1.Introduction and aim of work	1
2.Review of literature	4
2.1 Cancer	4
2.2 Epidemiology of breast cancer	5
2.3 Risk factors of breast cancer	7
2.4 Classification of breast cancer-screening and diagnosis.....	14
2.4.1 Staging of breast cancer.....	14
2.4.2 Special types of invasive carcinoma.....	17
2.4.3 The histological grading of breast cancer	19
2.4.4 The immune histochemistry classification of breast cancer.....	19
2.4.5 Screening and diagnosis of breast cancer	22
2.5 Tumor and molecular bio-markers	24
2.6 Treatment of breast cancer	38

3. Subjects, materials and methods.....	41
3.1 Subjects	41
3.1.1 Ethical statement	41
3.1.2 Groups	41
3.1.3 Inclusion criteria.....	42
3.1.4 Exclusion criteria.....	42
3.1.5 Data collected from the recorded in malignant patient's files... 	43
3.2 Sample collection and storage.....	44
3.3 Materials and methods.....	45
3.3.1 Liver function tests	45
3.3.2 Kidney function tests	51
3.3.3 Measurement of tumor and molecular biomarkers	55
3.3.3.1 Measurement of carcino-embryonic antigen.....	55
3.3.3.2 Measurement of human serum cancer antigen 15.3.....	58
3.3.3.3 Measurement of serum epithelial-cadherin (E-cadherin).....	61
3.3.3.4 Measurement of sex determining region-y box 11(SOX11)... 	65
3.3.3.5 Measurement of B-cell lymphoma /leukemia 11A (BCL11A)..	70
3.4 Statistical analysis	74

4. Results.....	75
4.1 Clinical data of the studied groups	75
4.2 Laboratory investigations	77
4.3 Serum CEA	81
4.4 Serum CA15.3	82
4.5 Serum E-cadherin	83
4.6 Serum SOX11	85
4.7 Serum BCL11A.....	87
4.8 Clinical and biological analysis of cancerous and non-cancerous study populations	88
4.9 Association between the studied markers among breast cancer patients and cancer sub-types	89
4.10 Association between the studied markers and TNM staging among breast cancer patients.....	90
4.11 Studied markers ROC curves.....	92
4.12 Correlations analysis between the studied markers.....	95
5. Discussion.....	97
6. Summary and conclusion.....	108

7. Recommendations.....	113
8. References	114
9. Arabic Summary.....	١

List of abbreviations

<u>Abbreviation</u>	<u>Definition</u>
AJCC	American Joint Committee on Cancer
ALT	Alanine Transaminase
AST	Aspartate Transaminase
AUC	Area Under The Curve
BC	Breast Cancer
BIRADS	Breast Imaging reporting and Data base System
BCL11A	B-Cell Lymphoma/Leukemia 11A
BRCA1	Breast Cancer Gene One
BRCA2	Breast Cancer Gene Two
CA15.3	Cancer Antigen 15.3
CEA	Carcino Embryonic Antigen
CI	Confidence Interval
C2H2	Cysteine two and Histidine two
E-cadherin	Epitheilal Cadherin
EDTA	Ethyelene Diamine Tetra Acetic Acid
ELISA	Enzyme Linked Immunosorbent Assasy
EMT	Epithelial Mesecnchymal Transition
ER	Estrogen Receptor
HRP	Horseradish peroxidise
HER-2	Human Epidermal Growth Factor Receptor-2
IDC	Invasive Ductal Carcinoma
ILC	Invasive Lobular Carcinoma
IHC	Immuuno-Histochemistry

LN	Lymph-Nodes
MRI	Magnetic Resonance Image
NCI	National Cancer Institute
O.D	Optical Density
PR	Progesterone Receptor
ROC	Receiver Operating Characteristics
SNAIL	Snail Family Transcriptional Repressor 1
SOX	SEX-Determining Region Y-Box
TMB	Tetramethylbenzidine
TNM	Tumor Size-Lymph Node –Metastasis Staging
TFs	Transcription Factors
TNBC	Triple Negative Breast Cancer
ZEB-1	Zinc Finger E-Box-1

Figure no.	Title	Page no.
1	Illustration of the carcinogenesis phases.	5
2	New cases and deaths from cancer in Egypt and prevalence by site	6
3	A bar chart of the regional-specific incidence and mortality age-standardized rates for breast cancer in 2018.	7
4	Mammary gland development.	11
5	Histological types and classification of breast cancer.	18
6	Location of <i>E-cadherin</i> gene.	27
7	Schematic representation of E-cadherin mediated cell–cell adherens junctions.	29
8	The epigenetic regulation of <i>E-cadherin</i> gene and the involvement of EMT process in breast carcinogenesis.	30
9	The molecular structure of SOX11.	32
10	Inhibiting cancer initiating cells by SOX11.	35
11	BCL11A expression from lymphoid progenitors.	37
12	The whole enrolled subjects study population chart.	44
13	Standard curve of CEA.	57
14	Standard curve of CA 15.3.	60
15	Standard curve of E-cadherin.	64
16	Standard curve of SOX11.	69

17	Standard curve of BCL11A.	73
18	Serum ALT levels of the studied groups.	77
19	Serum AST levels of the studied groups.	78
20	Serum Urea levels of the studied groups.	79
21	Serum creatinine levels of the studied groups.	80
22	Serum CEA levels of the studied groups.	81
23	Serum CA 15.3 levels of the studied groups.	82
24	Serum E-cadherin levels of the studied groups.	83
25	Serum E-cadherin levels among different breast cancer types.	84
26	Serum SOX11 levels of the studied groups.	85
27	Serum SOX11 levels among different stages.	86
28	Serum BCL11A levels among different groups.	87
29	ROC curves for the studied markers single and combined.	94
30	Correlation between SOX11 and BCL11A.	96
31	Correlation between SOX11 and CA15.3.	96